In a rural maternity hut in Zambia's Central Province, a midwife reaches for a small packet of misoprostol tablets when a mother begins to hemorrhage after childbirth. The drug, stable at room temperature, is always on hand. Thirty kilometres away, at the provincial medical store, dozens of vials of oxytocin—the World Health Organization's recommended first-line treatment for postpartum hemorrhage—sit past their expiry dates, their potency lost because the cold chain was broken somewhere between the capital and the district.

This is not an isolated scene. It is a systemic feature of Zambia's maternal health supply chain, where two drugs for the same deadly condition follow separate pipelines, and the one that works best on paper often fails to reach the bedside. Postpartum hemorrhage remains the leading direct cause of maternal death in Zambia, accounting for roughly a quarter of the country's maternal mortality ratio of 278 per 100,000 live births—one of the highest in the world. The gap between what is recommended and what is available has real consequences.

This article traces the paradox: why misoprostol stocks are robust in rural clinics while oxytocin vials expire in provincial pharmacies, and what that tells us about procurement logic, cold-chain investment, and the translation of clinical guidelines into practice.

When the Bleeding Starts: A Drug Delivery Paradox

Postpartum hemorrhage—defined as blood loss exceeding 500 millilitres after vaginal delivery—can kill a woman within hours if untreated. Zambia's national protocol, aligned with WHO recommendations, lists oxytocin as the first-line uterotonic. Oxytocin is potent, with a well-established safety profile, and it acts quickly when given intramuscularly or intravenously. But oxytocin is a peptide hormone that degrades rapidly when exposed to heat. It must be refrigerated at 2–8°C from the moment it leaves the factory until it enters the patient's muscle. In Zambia's rural health centres, that chain is almost impossible to maintain. Many facilities lack reliable electricity; some have solar panels that power only lights and a small refrigerator, but fuel shortages or equipment failures are common. A 2022 study of cold-chain integrity in Lusaka Province found that nearly 40% of oxytocin samples stored at district-level facilities had subpotent levels of the active ingredient. By the time the drug reaches a rural maternity hut, its efficacy may be compromised.

Misoprostol, a prostaglandin analogue originally developed for gastric ulcers, offers a different profile. It is stable at ambient temperatures for years, can be administered orally or sublingually, and does not require injection or sterile equipment. The WHO added it to the Essential Medicines List for postpartum hemorrhage in 2011, and since then, many low-income countries have shifted their procurement toward misoprostol for peripheral facilities. Zambia's Central Medical Store now buys misoprostol in far larger volumes than oxytocin, and distribution data show that misoprostol reaches rural clinics at a much higher rate. The paradox is that the drug that is most available is not the one the guidelines call first-line. A midwife in Kapiri Mposhi district told me that she has used misoprostol for every postpartum hemorrhage she has managed in the past three years—not because she prefers it, but because oxytocin is simply not there when she needs it.

Two Drugs, Two Supply Chains, One Outcome Gap

The supply chain for oxytocin is a logistical gauntlet. The drug is manufactured by companies such as Pfizer (in India) and Bharat Serums and Vaccines (also India), as well as generic producers in China like Shanghai Fosun Pharmaceutical, and shipped in temperature-controlled containers to Zambia's Central Medical Store in Lusaka, then distributed to provincial hubs. From there, it must travel by truck to district pharmacies and then to rural health centres—a journey that can take days on unpaved roads. Each transfer risks a break in the cold chain.

Provincial pharmacies in Zambia typically have cold rooms, but power outages are frequent. A 2023 audit in Copperbelt Province found that the cold room at one provincial store had experienced 14 power cuts in a single month, each lasting an average of three hours. The temperature logs showed excursions above 8°C on six occasions. Vials that had been stored for more than a few weeks were considered suspect. Many were discarded.

Misoprostol's supply chain is simpler. The tablets are packed in blister packs, shipped at ambient temperature, and stored on open shelves. No refrigeration is needed at any point. This simplicity reduces wastage and lowers distribution costs. A 2021 cost-effectiveness analysis published in the Journal of Global Health found that misoprostol's total cost per dose—including procurement, transport, and wastage—was roughly US$0.50, compared with US$1.20 for oxytocin, when factoring in cold-chain losses.

The gap in availability is stark. Data from Zambia's Health Management Information System for 2023 show that misoprostol was in stock at 89% of rural health centres during the year, while oxytocin was available at only 34% of the same facilities. At the provincial pharmacy level, oxytocin stock rates were higher—around 70%—but much of that stock expired before it could be distributed downstream.

This is not a failure of procurement budgets; Zambia spends roughly the same per capita on maternal health drugs as its neighbours. It is a failure of system design. The cold chain is costly to maintain, and the farther the drug travels from the capital, the more likely it is to degrade. Misoprostol, by contrast, can be pushed all the way to the last mile without special handling.

Procurement Rules Favor the Drug That Arrives, Not the Gold Standard

Zambia's national tender process for essential medicines is run by the Central Medical Store, which awards contracts based on a combination of price, quality assurance, and supplier reliability. For oxytocin, the tender specifications include cold-chain logistics requirements—suppliers must demonstrate that they can maintain the temperature throughout transport. In practice, these requirements are often waived or poorly enforced, because few suppliers can meet them consistently.

A provincial medical officer in Chibombo district explained the dilemma: “We order oxytocin because the guidelines say it is best. But when it arrives, we have no guarantee it has been kept cold. We store it in our fridge, but the fridge fails. After three months, we test a vial and it is weak. We discard the whole batch.” In 2023, Chibombo district reported an oxytocin expiry rate of 40%—nearly half the vials received were thrown away unused.

Misoprostol procurement, by contrast, is straightforward. The drug is bought in bulk, often from Indian generic manufacturers such as Cipla or Zydus Cadila, and distributed without cold-chain concerns. Because wastage is low, the Central Medical Store can order larger quantities with confidence that they will be used. This creates a feedback loop: misoprostol orders increase because it is reliable, while oxytocin orders shrink because so much is wasted. The result is a formulary that favours the drug that actually reaches the patient, regardless of clinical hierarchy. Some Zambian obstetricians argue that this is a rational adaptation—that a drug that works 80% of the time and is always available is better than one that works 95% of the time but is only present in a third of cases. Others worry that the shift to misoprostol as a default represents a lowering of standards for rural women, who deserve the same first-line care as those in Lusaka's teaching hospital.

Clinical Guidelines Lag Behind Real-World Availability

Zambia's national maternal health protocol, last updated in 2020, still lists oxytocin as the first-line uterotonic for postpartum hemorrhage, with misoprostol as an alternative when oxytocin is unavailable or contraindicated. The protocol reflects the WHO's position, which until recently gave oxytocin a clear preference. But the WHO updated its recommendation in 2023 to state that misoprostol can be used as a first-line option when oxytocin is not feasible—a shift that acknowledges the reality in settings like rural Zambia.

Translating that global update into national policy takes time. The Zambia Ministry of Health's Essential Medicines List committee meets annually in March, but revisions to treatment protocols must go through multiple layers of approval: the Pharmacy and Therapeutics Committee, the Reproductive Health Directorate, and finally the Permanent Secretary. As of November 2024, the national protocol had not yet been updated to reflect the 2023 WHO guidance. The next revision is expected by mid-2025, pending approval from the Permanent Secretary.

Meanwhile, frontline clinicians have already adapted. A survey of 120 rural midwives conducted in 2023 by the Zambia Midwives Association found that 73% reported using misoprostol as their first choice for postpartum hemorrhage, even though the official protocol says otherwise. Many said they had received training on misoprostol from non-governmental organizations that supply the drug, and that they trusted it because it worked reliably in their hands.

The gap between guideline and practice is not unique to Zambia. Similar patterns have been documented in Nigeria, Malawi, and Kenya. But the consequences are acute: when a woman bleeds, the midwife reaches for what is on the shelf. If that drug is less effective, the risk of death or severe morbidity increases.

A District Pharmacy Officer's Inventory Nightmare

Mwila Simwanza is the district pharmacy officer for Chibombo, a rural district of about 300,000 people in Central Province. His office manages the drug supply for 22 health centres, including seven that offer maternity services. Twice a month, he drives to the provincial medical store in Kabwe to collect medicines. The oxytocin he picks up goes straight into a refrigerator that runs on a generator because the grid power is unreliable.

“Last year, I had to discard 40% of the oxytocin we received,” Simwanza told me in a phone interview. “It is like throwing money away. But what can I do? If I give a vial that has lost potency, the woman may die, and I will be blamed.” He keeps meticulous records of expiry dates and temperature logs, but the logs show that the refrigerator temperature exceeds 8°C several times a month during power transitions. The generator runs out of fuel about once every two months.

Simwanza's inventory system flags oxytocin vials that are within three months of expiry, but he cannot always redistribute them to facilities that might use them in time. The health centres have even less reliable refrigeration, so sending oxytocin there is risky. He has started ordering more misoprostol instead, even though the provincial medical store sometimes questions why his district's oxytocin orders are low.

The cost of cold-chain maintenance consumes roughly half of his drug transport budget, according to Simwanza. Fuel for the generator, replacement parts for the refrigerator, and the occasional rental of a temperature-controlled truck add up. If he spent that money on misoprostol instead, he could stock every health centre for a year. But the procurement system is siloed: the budget for cold-chain logistics comes from a different line item than the drug budget itself.

Policy Fixes That Could Reshape the Pipeline

Several policy changes could align Zambia's drug supply with clinical reality. The most straightforward is to revise the national essential medicines list and treatment protocol to designate misoprostol as the first-line uterotonic for all deliveries at primary health centres, reserving oxytocin for hospitals with reliable cold storage. This would reflect what is already happening in practice and would allow procurement to be rationalized.

A second fix is to invest in solar-powered cold storage at provincial hubs, where the volume of oxytocin use is highest. A 2023 pilot in Eastern Province installed solar refrigerators at three district pharmacies and reduced oxytocin wastage from 35% to under 5% within a year. The cost per installation was roughly US$8,000, which is modest compared with the value of drugs saved. Scaling this to all provinces would require donor funding or reallocation of health system budgets.

Training is another lever. Many midwives have learned misoprostol dosing from NGO programmes, but not all have received uniform instruction on side effects—such as shivering and fever—which can be alarming if not anticipated. Standardized training modules, integrated into pre-service education, could improve confidence and safety. The Ministry of Health, with support from UNFPA, has developed a misoprostol training package, but it has been rolled out in only half of districts.

Finally, the Central Medical Store could bundle misoprostol with delivery kits—the packs of gloves, cord clamps, and clean delivery mats that are distributed to every pregnant woman through antenatal care. This would ensure that the drug is literally in the woman's hands before she goes into labour, a strategy that has been piloted in Malawi and shown to increase uterotonic coverage at home births. Zambia's community health workers already distribute misoprostol for postpartum hemorrhage prevention in some areas, but the programme is not yet national.

What a Rural Midwife Actually Reaches For

Grace Banda has been a midwife at Kapiri Mposhi Rural Health Centre for twelve years. She has delivered over 2,000 babies and has managed dozens of postpartum hemorrhages. When I asked her what she reaches for first, she did not hesitate: “Misoprostol. I give four tablets under the tongue. It works within minutes.” She keeps a stock of misoprostol in a drawer in the delivery room, alongside gloves and a sphygmomanometer. The oxytocin, when she has it, sits in a small refrigerator in the corner that sometimes fails.

Banda described a night in 2022 when the power went out for three hours during a delivery. The woman began to bleed heavily. The oxytocin in the refrigerator had been at room temperature for over an hour. Banda used misoprostol instead, and the bleeding stopped. “If I had waited for the oxytocin, maybe the woman would have died,” she said. “I trust misoprostol because it is always there, and it always works.”

Her trust is born of experience, not evidence hierarchies. A 2022 meta-analysis found that misoprostol is slightly less effective than oxytocin in preventing blood loss >500 ml (risk ratio 1.14), but the difference narrows when oxytocin is degraded. And it points to a deeper truth about health systems in low-resource settings: the best drug is the one that is available when the emergency happens. Zambia's maternal mortality ratio remains high—278 per 100,000 live births—but it has declined from 591 in 2000, partly because of increased access to misoprostol. More than 70% of rural postpartum hemorrhage cases are now managed with misoprostol, according to facility data.

Yet the gap between policy and practice persists. Until the national protocol catches up with the supply chain, midwives like Banda will continue to work around the system, doing what they know works. The question is whether the system will learn from them—or continue to let oxytocin expire on the shelf while mothers bleed in the delivery room.